Subsidiary’s YKYY036 Injection Receives Clinical Trial Approval from NMPA and FDA
October 16, 2026
Source: drugdu
43
People's Finance News, October 13th - Yuekang PharmaceuticalOn October 13, (688658) announced that its subsidiaries, Beijing Yuekang Kechuang Pharmaceutical Technology Co., Ltd. and Hangzhou Tianlong Pharmaceutical Co., Ltd. of Yuekang Pharmaceutical Group, recently received approval notices from the National Medical Products Administration (NMPA) for the use of YKYY036 injection for obese or overweight patients. Simultaneously, Beijing Yuekang Kechuang Pharmaceutical Technology Co., Ltd. recently received a letter from the U.S. Food and Drug Administration (FDA) approving its application for clinical trials of YKYY036 injection for overweight or obese patients.
Source: https://finance.eastmoney.com/a/202610133894283434.html
By editor
Copyright©2026 Ddu. All rights reserved.
Read more on
- Vir Biotechnology Enters Multi-Program Collaboration with Gilead Sciences to Develop Novel PRO-XTEN® Dual-masked T-cell Engagers for Solid Tumors October 16, 2026
- BioNTech’s mRNA Cancer Vaccine BNT113 Falls Short of Primary Endpoint in Phase 3 Trial October 16, 2026
- Foghorn Therapeutics’ Collaboration Terminated by Eli Lilly; Company to Lay Off 40% of Its Workforce October 16, 2026
- Visara (USA) Acquires Overseas Rights to Haite Bio’s HT006.2.2 Eye Drops October 16, 2026
- Asia Pacific Pharmaceutical’s Shengyao Guangyan Obtains a New Acne Drug Technology Achievement from Quzhou Fudan Research Institute October 16, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
